Macrophages activated by the Gram-negative bacterial product lipopolysaccharide switch their core metabolism from oxidative phosphorylation to glycolysis 1 . Here we show that inhibition of glycolysis with 2-deoxyglucose suppresses lipopolysaccharideinduced interleukin-1b but not tumour-necrosis factor-a in mouse macrophages. A comprehensive metabolic map of lipopolysaccharideactivated macrophages shows upregulation of glycolytic and downregulation of mitochondrial genes, which correlates directly with the expression profiles of altered metabolites. Lipopolysaccharide strongly increases the levels of the tricarboxylic-acid cycle intermediate succinate. Glutamine-dependent anerplerosis is the principal source of succinate, although the 'GABA (c-aminobutyric acid) shunt' pathway also has a role. Lipopolysaccharide-induced succinate stabilizes hypoxia-inducible factor-1a, an effect that is inhibited by 2-deoxyglucose, with interleukin-1b as an important target. Lipopolysaccharide also increases succinylation of several proteins. We therefore identify succinate as a metabolite in innate immune signalling, which enhances interleukin-1b production during inflammation.
1
Macrophages activated by the Gram-negative bacterial product lipopolysaccharide switch their core metabolism from oxidative phosphorylation to glycolysis 1 . Here we show that inhibition of glycolysis with 2-deoxyglucose suppresses lipopolysaccharideinduced interleukin-1b but not tumour-necrosis factor-a in mouse macrophages. A comprehensive metabolic map of lipopolysaccharideactivated macrophages shows upregulation of glycolytic and downregulation of mitochondrial genes, which correlates directly with the expression profiles of altered metabolites. Lipopolysaccharide strongly increases the levels of the tricarboxylic-acid cycle intermediate succinate. Glutamine-dependent anerplerosis is the principal source of succinate, although the 'GABA (c-aminobutyric acid) shunt' pathway also has a role. Lipopolysaccharide-induced succinate stabilizes hypoxia-inducible factor-1a, an effect that is inhibited by 2-deoxyglucose, with interleukin-1b as an important target. Lipopolysaccharide also increases succinylation of several proteins. We therefore identify succinate as a metabolite in innate immune signalling, which enhances interleukin-1b production during inflammation.
Activation of Toll-like receptors, notably Toll-like receptor 4, leads to a switch from oxidative phosphorylation to glycolysis in immune cells 1, 2 , similar to that occurring in tumours. In bone-marrow-derived macrophages (BMDMs), 2-deoxyglucose (2DG) specifically inhibits lipopolysaccharide (LPS)-and Bordetella pertussis-induced interleukin-1b (Il1b) transcription, but not tumour-necrosis factor-a (Tnf ) (Fig. 1a, b ) or interleukin-6 (Il6) ( Supplementary Figs 1 and 2 ) transcription. 2DG had no effect on invasion and growth of the bacteria in BMDMs ( Supplementary Fig. 3 ). The inhibitory effect of 2DG on LPSinduced IL-1b was evident in vivo. Inhibition of TNF-a in vivo was also evident, most probably because of an IL-1b-dependency on induction of TNF-a (Fig. 1c) . There was no effect on the induction of IL-6 in vivo ( Supplementary Fig. 4 ).
Supplementary Fig. 5 lists LPS-regulated genes affected by 2DG, including Il1b. Several hypoxia-inducible factor-1a (HIF-1a) targets were upregulated by LPS and downregulated with 2DG, including ankyrin repeat domain 37, lysyl oxidase and activating transcription factor 3.
LPS-induced HIF-1a protein but not messenger RNA expression in BMDMs was inhibited by 2DG ( Fig. 2a and Supplementary Fig. 6 ). To examine a direct functional relationship between HIF-1a and IL-1b, we found LPS-induced IL-1b protein expression was markedly increased under hypoxia (Fig. 2b) , TNF-a was not affected and, as previously shown 3 , IL-6 expression was inhibited ( Supplementary Fig. 7 ).
The prolyl hydroxylase (PHD) inhibitor dimethyloxallyl glycine, which stabilizes HIF-1a protein, also boosted LPS-induced Il1b mRNA ( Supplementary Fig. 8 ). Conversely, pre-treating LPS-stimulated BMDMs with a cell-permeable a-ketoglutarate (a-KG) derivative, which increases PHD activity, depleting HIF-1a, significantly reduced LPS-induced Il1b mRNA (Fig. 2c) . a-KG inhibited expression of both LPS-induced HIF-1a and IL-1b protein in a dose-dependent manner a, b, Il1b and Tnf messenger RNA in 100 ng ml 21 LPS-or 1 3 10 5 B. pertussisstimulated BMDMs 6 2DG (1 mM) pre-treatment for 3 h (n 5 3). c, Mice injected intraperitoneally with or without 2DG (2 g kg
21
) or PBS for 3 h, then 15 mg kg 21 LPS or PBS for 1.5 h. Serum concentrations of IL-1b and TNF-a: LPS, n 5 15; LPS 1 2DG, n 5 14; 2DG, n 5 8; vehicle, n 5 5. Error bars, s.e.m. *P , 0.05; **P , 0.01. (Fig. 2d) . Induction of IL-1b was attenuated in Hif1a deficient macrophages (Fig. 2e) .
Inspection of human (IL1B) and murine (Il1b) gene sequences showed a conserved canonical HIF-1a binding site approximately 300 base pairs upstream from the transcription start site in the human gene, and at position 2357 in the mouse gene 4, 5 . Chromatin immunoprecipitation (ChIP)-PCR analysis in LPS-stimulated BMDMs showed HIF-1a bound near the 2300 position of Il1b at 4, 12 and 24 h, which was inhibited by 2DG (Fig. 2f) . LPS-induced Il1b luciferase activity, which was blocked by 2DG, had substantially reduced activity when 2357 in the Il1b (Fig. 2g) or 2300 in IL1B ( Supplementary  Fig. 9 ) promoter was mutated. LPS-induced HIF-1a binding to the 2300 position of the Il1b promoter by ChIP analysis was abolished by pre-treatment with a-KG (Fig. 2h) . Therefore IL-1b is a direct target of HIF-1a, with HIF-1a probably having a late effect more associated with the extended expression of IL-1b given the kinetics, supporting previous data 6, 7 . The inhibition of IL-1b but not TNF-a induction by 2DG is therefore explained by the HIF-1a dependency in the IL1B gene. Hif1a deficiency also rescues mice from LPS-induced sepsis 7 but how HIF-1a protein is regulated by LPS is still unknown.
Several groups have shown stabilization of HIF-1a by reactive oxygen species after LPS stimulation 8, 9 , which we confirmed (Supplementary Fig. 10 ). Also, HIF-1a is stabilized by the PLC/PKC pathway 9 ; however, treatment of BMDMs with specific inhibitors to PLC/PKC had no effect on LPS-induced HIF-1a protein expression at 24 h (Supplementary Fig. 11 ).
Because both 2DG and a-KG could inhibit HIF-1a accumulation and consequently induction of IL-1b, we considered that the reported change in metabolism induced by LPS must be required for this response. We therefore next examined the metabolic profile of LPS-stimulated BMDMs by flux analysis, a metabolomic screen and microarray analysis. Extracellular flux analysis showed increased glucose use by LPS-stimulated BMDMs (Fig. 3a) . This is due to increased glycolysis as measured by an increase in extracellular acidification rate accompanied by a decrease in oxygen consumption rate after LPS stimulation ( Fig. 3a and Supplementary Fig. 12 ), confirming LPS induces the 'Warburg effect' of aerobic glycolysis. Table 1 . Error bars, s.e.m. *P , 0.05; **P , 0.01.
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The metabolomic screen confirmed this switch in metabolism with 73 metabolites changing out of 208 analysed ( Supplementary Fig. 13 ). Glycolytic intermediates accumulated in 24 h of LPS stimulation. Despite decreased mitochondrial respiration, the tricarboxylic acid (TCA) cycle intermediates fumarate, malate and succinate accumulated. Succinate continued to accumulate between 4 and 24 h, and isocitrate was significantly depleted. Despite a minor increase in citrate at 24 h, there was significant accumulation of di-and triacylglycerols, indicating an increased rate of fatty-acid synthesis. Pentose phosphate pathway intermediates increased, as did the downstream products of purine and pyrimidine metabolism, guanosine, hypoxanthine and inosine ( Supplementary Fig. 13 ). These substrates are necessary to meet the increased demand for energy and nucleic acid synthesis of these highly active cells.
Microarray analysis showed the metabolomic changes correlated with the gene expression profiles of LPS-stimulated BMDMs. Thirtyone metabolic enzyme/transporter-related genes were differentially expressed after 24 h of LPS treatment (Supplementary Fig. 14) . The glucose transporters GLUT1, hexokinase 3, 6-phosphofructo-2-kinase/ fructose-2,6-biphosphatase 3, phosphoglucomutase-2 and enolase 2 were significantly upregulated, confirming an increase in glycolysis. Lack of mitochondrial activity can be explained by decreased expression of malate dehydrogenase and isocitrate dehydrogenase. In addition, increased amounts of citrate and fatty acids suggested that activity was being diverted away from the TCA cycle for biosynthetic needs. The metabolic screen and flux analysis therefore showed that although there was an overall decrease in TCA cycle activity and mitochondrial respiration at 24 h LPS treatment, there was an accumulation of the key TCA cycle intermediate, succinate.
Further analysis by liquid chromatography-mass spectrometry (LC-MS) showed that LPS caused a 30-fold increase in succinate at 24 h, which equates to an increase in basal succinate from 25 ng to 1 mg per 2 3 10 6 cells. Pre-treatment with 2DG reduced intracellular succinate, in a dose-dependent manner (Fig. 3b) .
Succinate can be transported from the mitochondria through the dicarboxylic acid transporter to the cytosol, where in excess it impairs PHD activity (by product inhibition) leading to HIF-1a stabilization and activation. This phenomenon has been defined as 'pseudohypoxia' 10 . This effect is blocked by a-KG, the substrate for PHD that generates succinate as a by-product in HIF-1a hydroxylation 10, 11 . We had observed that a-KG inhibited stabilization of HIF-1a and induction of IL-1b (Fig. 2) , indicating that the stabilization of HIF-1a by LPS was probably dependent on the rise of succinate. We tested this further and found that cell-permeable diethylsuccinate alone had no effect on expression of HIF-1a ( Supplementary Fig. 15 ) or Il1b (Fig. 3c) , because LPS is required to induce Hif1a mRNA ( Supplementary  Fig. 6 ). However, in combination with LPS, succinate profoundly augmented Il1b mRNA expression (Fig. 3c) . This supports previous work in which succinate boosted LPS-induced IL-1b in dendritic cells 12 . Succinate amounts are regulated by succinate dehydrogenase. Diethylbutylmalonate, a succinate dehydrogenase inhibitor, increased LPS-induced Il1b mRNA (Fig. 3d) . Both diethylsuccinate and diethylbutylmalonate increased HIF-1a and IL-1b protein in LPS-treated BMDMs (Supplementary Fig. 15 ). Diethylsuccinate also increased mRNA of the LPS-induced HIF-1a target Phd3 (also known as Egln3) (ref. 13) (Supplementary Fig. 16 ). The effect of diethylsuccinate on IL-1b was due to HIF-1a as LPS-stimulated BMDMs from Hif1a deficient mice had less IL-1b protein and mRNA than wild type, and pre-treatment with diethylsuccinate had no significant effect. IL-6 and TNF-a were unaffected in Hif1a deficient macrophages (Supplementary Fig. 17 ). Therefore LPS-induced succinate can act as a signal to increase IL-1b expression through HIF-1a.
Certain metabolic enzymes have been shown to undergo succinylation 14 . We observed an increase in succinylation of proteins in response to LPS, which was reduced by 2DG in a dose-dependent manner (Fig. 3e) . This was confirmed by a [ 32 P]NAD assay ( Supplementary   Fig. 18 ). LPS treatment resulted in a twofold increase in protein succinylation, which was inhibited by 36% with 2DG treatment (data not shown). The expression of Sirt5 (a recently reported desuccinylase and demalonylase 14 ) was inhibited by LPS, suggesting reduced desuccinylase activity (Supplementary Fig. 19 ). BMDMs treated for 24 h with LPS also had a significantly altered NAD/NADH ratio favouring NADH, thus providing little NAD 1 substrate for SIRT5 activity (Supplementary Fig. 20 ). This decrease in the NAD/NADH ratio also provides further evidence of enhanced glycolysis and lower respiration. The increase in protein succinylation could therefore be explained by an increase in succinate and a decrease in the expression and activity of the desuccinylase SIRT5.
The relative abundance of proteins in BMDM lysates enriched using a succinyl lysine antibody were detected using LC-MS. Figure 3f represents the mean exponentially modified protein abundance index (emPAI) values (relative quantity) of proteins from unstimulated and LPS-stimulated samples, an enrichment of succinylated proteins being evident in the LPS-treated BMDMs. The increased succinylation of malate dehydrogenase (Supplementary Table 1 ) has previously been reported in animal tissue 14 . Other proteins identified include glyceraldehyde-3-phosphate dehydrogenase, glutamate carrier 1, L-lactate dehydrogenase A chain and transaldolase. The consequence of succinylation of these proteins, a covalent modification activated by LPS not previously reported, is now under investigation.
A dysfunctional TCA cycle in LPS-stimulated BMDMs pointed towards an alternative source of succinate. The microarray screen showed significantly higher concentrations of glutamine transporter (Slc3a2) at 24 h. Succinate can be derived from glutamine through anerplerosis by a-KG. We confirmed LPS induction of Slc3a2 mRNA (Fig. 4a) . SLC3A2 mRNA expression has previously been shown to increase during intestinal inflammation and is regulated by Sp1 and NF-kB 15 . Blocking the NF-kB pathway with a specific MyD88 inhibitory peptide significantly reduced LPS-induced Slc3a2 mRNA expression (Supplementary Fig. 21 ). Knockdown of SLC3A2 by short interfering RNA in human PBMCs ( Supplementary Fig. 22 ) significantly reduced LPS-induced IL-1b expression (Fig. 4b) , but had no effect on IL-6 or TNF-a ( Supplementary Fig. 22 ). This was also demonstrated in the RAW-264 macrophage cell line (Supplementary Fig. 23 ).
In addition to anerplerosis, succinate can also be derived from glutamine through the 'GABA (c-aminobutyric acid) shunt' pathway. Gene expression analysis and metabolomics showed LPS-induced GABA transporters (SLC6A13, SLC6A12) and increased GABA production ( Supplementary Fig. 13 ). The increase in GABA was further confirmed by LC-MS (Fig. 4c) .
Next we traced the metabolism of [ (Fig. 4d ). This showed a marked increase in succinate production from labelled glutamine. Of the total succinate pool in the LPS-treated BMDMs, 18.4 6 0.9% (n 5 4; 6 SEM) was labelled after 3 h incubation, as shown by the ratio of [ 13 C 4 ]succinate (heavy labelled succinate) to the sum of all measured succinate isotopomers. This represents a 14-fold increase in succinate relative to non-LPS-treated BMDMs. Treatment of BMDMs with the specific, irreversible inhibitor of the key 'GABA shunt' enzyme GABA transaminase, vigabatrin 16 , reduced the percentage of labelled succinate to 16.0 6 0.6% (n 5 4; P 5 ,0.05), representing a 9.4-fold elevation over the concentrations of succinate attained with vigabatrin alone. This represented a 33% decrease compared with the samples from BMDMs not treated with vigabatrin (Fig. 4e) . The elevation in succinate in response to LPS derived from glutamine is therefore largely from anerplerosis by a-KG although a proportion is derived from the 'GABA shunt'.
Pre-treatment of BMDMs with vigabatrin significantly reduced LPS-induced HIF-1a and IL-1b protein (Fig. 4f) as well as Phd3 mRNA (Supplementary Fig. 24 ). The inhibitory effect was specific for IL-1b as vigabatrin inhibited Il1b mRNA expression (Fig. 4g) but not TNF-a protein amounts or IL6 mRNA (Supplementary Fig. 24 ).
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This was also evident in vivo as a prescription formulation of vigabatrin (Sabril) reduced LPS-induced IL-1b (Fig. 4h) but had no effect on IL-6 ( Supplementary Fig. 25 ). Similar to 2DG, the inhibitory effect of vigabatrin on TNF-a is probably due to downstream signalling of IL1b ( Supplementary Fig. 25 ). Similarly vigabatrin reduced IL-1b serum amounts in response to Salmonella infection (Fig. 4i) . This was consistent with the greater bacterial loading in the spleens of vigabatrintreated mice (Supplementary Fig. 26 ). In a model of sepsis, vigabatrin also protected mice, presumably by blocking HIF-1a activation (P , 0.001) (Fig. 4j) .
Our study therefore shows that chronic activation of macrophages with LPS causes an increase in intracellular succinate by glutaminedependent anerplerosis and the 'GABA-shunt' pathway. Succinate acts as an endogenous danger signal to stabilize HIF-1a, which in turn specifically regulates gene expression of Il1b and other HIF-1a-dependent genes and leads to protein succinylation (Fig. 4k) . The role of the 'GABA shunt' is also of substantial interest. Vigabatrin is used clinically to treat epilepsy, as it can increase GABA, which is an inhibitory neurotransmitter. However, adverse effects include significant increased risk of infections 17 , which could be caused by limitation of the GABA shunt in macrophages.
Succinate therefore joins other signals derived from mitochondria, including cytochrome C (ref. 18) , and mitochondrial DNA 19 that have a role in signalling cell trauma. Succinate can be released to signal through GPR91, which synergizes with Toll-like receptors 12 . High succinate concentrations have been detected in the plasma of patients with peritonitis 20 , and in the urine and plasma of diabetic and metabolic disease rodent models 21, 22 . In addition, patients harbouring mutations in succinate dehydrogenase have increased HIF-1a activity 23, 24 and circulating succinate 25 . Succinate activates HIF-1a in tumours 10, 26 , 
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indicating an important similarity between inflammation and cancer. The inflammatory process may have a tumorigenic effect by increasing succinate. The identification of succinate as an inflammatory signal may therefore be important for our understanding of innate immunity in both inflammatory diseases and cancer.
METHODS SUMMARY
Female C57BL/6 mice were from Harlan UK. BMDMs from Hif1a flox/flox/LysMcre and wild-type controls, Hif1a flox/flox littermate controls, were obtained from M. Whyte. All experiments had previous ethical approval from Trinity College Dublin Animal Research Ethics Committee. BMDMs were prepared as described previously 27 . Unless stated, 100 ng ml 21 LPS and 5 3 10 5 cells per millilitre BMDMs were used in in vitro experiments. Two-tailed t-tests measured significance of expression of genes with different treatments. Western blot analysis was performed as previously described 28 . Reactive oxygen species were measured on LPS-stimulated BMDMs as previously described 29 . ELISAs for IL-1b (R&D, Quantikine), IL-6 and TNF-a (R&D, Duoset) were performed according to the manufacturer's instructions. Microarray was performed on the Illumina microarray platform. Genes with fold changes in expression greater than 1.5 and Benjamini-Hochberg adjusted t-test-based P values less than 0.05 were considered significant. Metabolic profiling was in the positive ion MS mode using an LC system. Metabolites with fold change in amounts greater than 10% and P values less than 0.05 were considered to be statistically significant. Succinate and GABA amounts were measured by LC-MS analysis. ChIP-PCR using HIF-1a antibody and primers specific for the 2300 position of the Il1b and IL1B genes were performed using a modification of the Millipore/Upstate protocol (MCPROTO407). PBMCs were isolated and transfected with short interfering RNA as described previously 28 using Hs_SLC3A2_1, target sequence AATCCTGAGCCTACT CGAATC (Qiagen). RAW-264 cells were transfected as described previously 28 using Mm_Slc3a2_1 target sequence CAGAAGGATGAAATCAATGAA (Qiagen). The plasmid containing human IL1B, pGL3-IL1 (a gift from J. Kim) and a chloramphenicol acetyltransferase plasmid containing 24093 to 145 of the mouse Il1b were mutated using the QuikChange lightning site directed mutagenesis kit (Agilent) according to the manufacturer's instructions. The NAD/NADH ratio was analysed according to the manufacturer's instructions (Biovision K337-100).
